Study #2021-0612
A Phase I/Ib, open-label, multi-center study of DFF332 as a single agent and in combination with Everolimus or IO agents in patients with advanced/relapsed ccRCC and other malignancies with HIF2a stabilizing mutations
MD Anderson Study Status
Not Accepting
Treatment Agent
DFF332, RAD001, PDR001, NIR178
Description
This is first in human study of DFF332, a small molecule that targets a protein called HIF2α. By acting on HIF2α, DFF332 may be able to stop the growth of certain types of cancer. DFF332 will be tested at different doses as single agent and in combination with Everolimus (RAD001, an mTOR inhibitor), and also in combination with Spartalizumab (PDR001, an anti-PD1) plus Taminadenant (NIR178, an adenosine A2A receptor antagonist), in patients with advanced clear cell renal cell carcinoma and other malignancies with HIF stabilizing mutations.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Carcinoma, Renal Cell
Study phase:
Phase I
Physician name:
Nizar Tannir
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-844-317-6206
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.